...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!
Top-Line Data Expected September 2019 for BETonMACE Phase 3 Cardiovascular Outcomes Trial for Apabetalone
Message: Resverlogix Announces Participation at Prominent Industry and Investor Conferences
CALGARY, Alberta, March 11, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at leading industry and investor conferences during the month of March including, the American College of Cardiology’s (ACC) 68th Annual Scientific Session, the 31st Annual ROTH Conference, BIO-Europe Spring and the 14th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD).
Of note, during AD/PD, Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic Lou Ruvo Brain Health Center, Las Vegas, Nevada, will deliver an oral presentation on Alzheimer’s Disease Treatment Strategies titled: Apabetalone (An Epigenetic BET-Inhibitor Small Molecule): A Sub-Study Evaluating Effects on Cognition In Diabetes Patients With Cardiovascular Disease.
In addition, Dr. Ewelina Kulikowski, Senior Vice President, Research & Development for the Company will deliver an oral presentation during AD/PD titled: The Epigenetic Inhibitor Apabetalone Downregulates Brain Endothelial and Microglial Cell Activation That Contributes to Neurodegenerative Disease.
Through participation at major conferences and events, the Company continues to highlight apabetalone – the first bromodomain and extra-terminal (BET) inhibitor in a Phase 3 clinical trial, BETonMACE for high-risk vascular disease – and its ability to regulate multiple biological pathways that underlie, and are known to contribute to, cardiovascular, diabetes, kidney and neurodegenerative diseases.
BETonMACE is fully enrolled and is expected to be completed in the first half of 2019.
ACC 2019, New Orleans, LA, USA
- March 16th, 2019
- Poster Session: Apabetalone, an Epigenetic BET Inhibitor in a Phase 3 Trial, Inhibits Vascular Inflammation and Cellular Adhesion Leading to Beneficial Outcomes in CVD Patients
- March 18th, 2019
- Poster Session: BET Protein Inhibition and Cognition: A Pre-Specified Substudy of the BETonMACE Phase 3 Trial Evaluating Apabetalone in Patients With Diabetes and Acute Coronary Syndrome
31st Annual ROTH Conference, Orange County, CA, USA, March 17 – 19, 2019
- Ahead of the conference, a pre-recorded webcast will be accessible on the afternoon of March 11, 2019. Access the webcast by visiting our events page HERE.
BIO-Europe Spring 2019, Vienna, Austria, March 25 – 27, 2019
AD/PD 2019, Lisbon, Portugal
- March 27th, 2019
- Poster Session: The Epigenetic Inhibitor Apabetalone Downregulates Brain Endothelial and Microglial Cell Activation That Contributes to Neurodegenerative Disease
- March 30th, 2019
- Presentation Title: Apabetalone (An Epigenetic BET-Inhibitor Small Molecule): A Sub-Study Evaluating Effects on Cognition In Diabetes Patients With Cardiovascular Disease
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the timing of the BETonMACE trial and the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, and Orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Please login to post a reply